UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2024
America Great Health
(Exact name of registrant as specified in charter)
Wyoming
(State or other jurisdiction of incorporation)
| 0-27873 | | 98-0178621 |
| (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
| 1609 W Valley Blvd., #338, Alhambra, CA | | 91803 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code: (626) 576-1299
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a material definitive agreement
On September 22, 2024, America Great Health (the “Company”) entered into a Framework Agreement for Product Project Cooperation (the “Contract”) with Xinjiang Wuse Guoshan Supply Chain Management, Co. Ltd., a Chinese company (“Xinjiang Wuse”). The Company’s products are a series of ion peptide products developed using “protein surface ion modification technology,” achieving a world-leading position in both research and production. Xinjiang Wuse, with its strategic location in Xinjiang, China, has the advantageous resources based on the homology of medicine and food in Xinjiang, and has built a supply chain operation platform for medicine and food from the same source of supply base, product selection center, distribution center and urban warehouse.
Under the Contract, the high-end biotechnology products developed and produced by the Company are consistent with Xinjiang Wuse's product system and will be implanted into its marketing network system as high-end products in the city warehouse. The Company guarantees that its products have relevant compliance qualifications to enter the Chinese market. Xinjiang Wuse designs and distributes marketing channel plans suitable for the Company's products based on the needs of each city's warehouse area.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: October 25, 2024
By: /s/ Mike Wang
Name: Mike Wang
Title: President
false
0001098009
true
0001098009
2024-09-22
2024-09-22